Q4 2018 13F Holders as of 12/31/2018
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
20.8M
-
Number of holders
-
317
-
Total 13F shares, excl. options
-
163M
-
Shares change
-
+5.24M
-
Total reported value, excl. options
-
$5.36B
-
Value change
-
+$29.6M
-
Put/Call ratio
-
0.61
-
Number of buys
-
159
-
Number of sells
-
-203
-
Price
-
$32.87
Significant Holders of Nektar Therapeutics, Inc. - Common Stock, par value $0.0001 per share (NKTR) as of Q4 2018
438 filings reported holding NKTR - Nektar Therapeutics, Inc. - Common Stock, par value $0.0001 per share as of Q4 2018.
Nektar Therapeutics, Inc. - Common Stock, par value $0.0001 per share (NKTR) has 317 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 163M shares
.
Largest 10 shareholders include FMR LLC (26M shares), PRIMECAP MANAGEMENT CO/CA/ (19.4M shares), Vanguard Group Inc (18.3M shares), OppenheimerFunds, Inc. (17.3M shares), BlackRock Inc. (13M shares), WELLINGTON MANAGEMENT GROUP LLP (10.7M shares), STATE STREET CORP (6.79M shares), JANUS HENDERSON GROUP PLC (2.53M shares), FIRST TRUST ADVISORS LP (2.31M shares), and GEODE CAPITAL MANAGEMENT, LLC (2.23M shares).
This table shows the top 317 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.